Product Description
The active ingredient in Aes-103 is 5-hydroxymethyl furfural, a naturally occurring small molecule that is chemically related to glucose. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01987908)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hypoxia|Anemia, Sickle Cell
Phase 1: Anemia, Sickle Cell
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Aes-103-002 | P1 |
Completed |
Anemia, Sickle Cell |
2013-06-07 |
2019-03-19 |
Treatments |
|
| 2013-001534-18 | P2 |
Completed |
Anemia, Sickle Cell |
2015-03-16 |
2022-03-13 |
Treatments |
|
| Aes-103-003 | P2 |
Terminated |
Anemia, Sickle Cell |
2015-03-16 |
2021-05-26 |
||
| 13-4002H | P2 |
Completed |
Hypoxia |
2013-06-01 |
2019-03-19 |
Treatments |